Alterations in the homeostasis of phospholipids and cholesterol by antitumor alkylphospholipids

Lipids in Health and Disease

Volumn 9, Issue , 2010, Pages

  Jiménez Lápez, José M ^a   Ríos Marco, Pablo ^a   Marco, Carmen ^a   Segovia, Josefa L ^a   Carrasco, María P ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CERAMIDE; CHOLESTEROL; EDELFOSINE; ERUCYLPHOSPHOCHOLINE; GLYCEROLIPID; MILTEFOSINE; PERIFOSINE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID; SPHINGOLIPID; SPHINGOMYELIN; UNCLASSIFIED DRUG; ANTIPROTOZOAL AGENT; DRUG DERIVATIVE; PHOSPHORYLCHOLINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CELL LEVEL; CELL MEMBRANE; CELL SURVIVAL; CHOLESTEROL ESTERIFICATION; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CYTOSTASIS; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENDOPLASMIC RETICULUM; GENE EXPRESSION; GROWTH INHIBITION; HEPATOMA CELL; HOMEOSTASIS; HUMAN; LEISHMANIASIS; LIPID METABOLISM; LIPID RAFT; METHYLATION; NONHUMAN; REVIEW; SKIN METASTASIS; ARTICLE; BIOSYNTHESIS; CELL PROLIFERATION; ESTERIFICATION; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTIPROTOZOAL AGENTS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLESTEROL; ESTERIFICATION; HOMEOSTASIS; HUMANS; PHOSPHOLIPIDS; PHOSPHORYLCHOLINE;

EID: 77951761725     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-9-33     Document Type: Review

References (70)

1. Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects. WJ van Blitterswijk M Verheij, Curr Pharm Des 2008 14 2061 2074 10.2174/138161208785294636 18691116
2. The antiproliferative effect of hexadecylphosphocholine toward HL60 cells is prevented by exogenous lysophosphatidylcholine. K Boggs CO Rock S Jackowski, Biochim Biophys Acta 1998 1389 1 12 9443598
3. Induction of ceramide-mediated apoptosis by the anticancer phospholipid analog, hexadecylphosphocholine. T Wieder CE Orfanos CC Geilen, J Biol Chem 1998 273 11025 31 10.1074/jbc.273.18.11025 9556584
4. Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities. M Rybczynska M Spitaler NG Knebel G Boeck H Grunicke J Hofmann, Biochem Pharmacol 2001 62 765 772 10.1016/S0006-2952(01)00715-8 11551522
5. Structure-activity relationships of alkylphosphocholine derivatives: antineoplastic action on brain tumor cell lines in vitro. V Jendrossek K Hammersen B Erdlenbruch W Kugler R Krugener H Eibl M Lakomek, Cancer Chemother Pharmacol 2002 50 71 79 10.1007/s00280-002-0440-8 12111115
6. Early stage monitoring of miltefosine induced apoptosis in KB cells by multinuclear NMR spectroscopy. J Engelmann J Henke W Willker B Kutscher G Nössner J Engel D Leibfritz, Anticancer Res 1996 16 1429 1439 8694511
7. Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma. S Clive J Gardiner RC Leonard, Cancer Chemother Pharmacol 1999 44 Suppl 29 30 10.1007/s002800051114 10602908
8. Cellular transport and lipid interactions of miltefosine. G Barratt M Saint-Pierre-Chazalet PM Loiseau, Curr Drug Metab 2009 10 247 255 10.2174/138920009787846332 19442087
9. Oral miltefosine to treat leishmaniasis. J Soto P Soto, Biomedica 2006 26 Suppl 1 207 217 17361856
10. Miltefosine affects lipid metabolism in Leishmania donovani promastigotes. M Rakotomanga S Blanc K Gaudin P Chaminade PM Loiseau, Antimicrob Agents Chemother 2007 51 1425 1430 10.1128/AAC.01123-06 17242145
11. Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica. K Seifert M Duchne WH Wernsdorfer H Kollaritsch O Scheiner G Wiedermann T Hottkowitz H Eibl, Antimicrob Agents Chemother 2001 45 1505 1510 10.1128/AAC.45.5.1505-1510.2001 11302818
12. Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi. VB Saraiva D Gibaldi JO Previato L Mendonca-Previato MT Bozza CG Freire-de-Lima N Heise, Antimicrob Agents Chemother 2002 46 3472 3477 10.1128/AAC.46.11.3472-3477.2002 12384352
13. Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp. J Walochnik M Duchne K Seifert A Obwaller T Hottkowitz G Wiedermann H Eibl H Aspöck, Antimicrob Agents Chemother 2002 46 695 701 10.1128/AAC.46.3.695-701.2002 11850250
14. Mechanisms of action of phospholipid analogs as anticancer compounds. T Wieder W Reutter CE Orfanos CC Geilen, Prog Lipid Res 1999 38 249 259 10.1016/S0163-7827(99)00004-1 10664795
15. Induction of resistance to hexadecylphosphocholine in the highly sensitive human epidermoid tumour cell line KB. EA Fleer D Berkovic U Grunwald W Hiddemann, Eur J Cancer 1996 32A 506 511 10.1016/0959-8049(95)00566-8 8814699
16. In vitro and in vivo antitumoral activity of alkylphosphonates. UJ Ries EA Fleer A Breiser C Unger J Stekar K Fenneberg H Eibl, Eur J Cancer 1992 29A 96 101 1445752
17. Uptake, subcellular distribution and metabolism of the phospholipid analogue hexadecylphosphocholine in MDCK cells. CC Geilen T Wieder A Haase W Reutter DM Morré DJ Morré Biochim Biophys Acta 1994 1211 14 22 8123677
18. Effects of etherlipid analogs on cell membrane functions. D Berkovic JH Wernicke EA Fleer, J Exp Ther Oncol 2003 3 185 193 10.1046/j.1359-4117.2003. 01094.x 14567289
19. Changes of intracellular calcium, fatty acids and phospholipids during miltefosine induced apoptosis monitored by fluorescence- and 13C NMR-spectroscopy. J Henke J Engelmann B Kutscher G Nossner J Engel R Voegeli D Leibfritz, Anticancer Res 1999 19 4027 4032 10628349
20. Hexadecylphosphocholine inhibits phosphatidylinositol and phosphatidylcholine phospholipase C in human leukemia cells. D Berkovic M Goeckenjan S Luders W Hiddemann EA Fleer, J Exp Ther Oncol 1996 1 302 311 9414418
21. Differential regulation of phospholipase A2 in human leukemia cells by the etherphospholipid analogue hexadecylphosphocholine. D Berkovic S Luders M Goeckenjan W Hiddemann EA Fleer, Biochem Pharmacol 1997 53 1725 1733 10.1016/S0006-2952(97)00095-6 9264326
22. Modulation of phospholipase D by hexadecylphosphorylcholine: a putative novel mechanism for its antitumoral activity. L Lucas R Hernndez-Alcoceba V Penalva JC Lacal, Oncogene 2001 20 1110 1117 10.1038/sj.onc.1204216 11314048
23. The inhibition of cell signaling pathways by antitumor ether lipids. G Arthur R Bittman, Biochim Biophys Acta 1998 1390 85 102 9487143
24. Alkyl-lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis. GA Ruiter M Verheij SF Zerp WJ van Blitterswijk, Int J Radiat Oncol Biol Phys 2001 49 415 419 10.1016/S0360-3016(00)01476-0 11173135
25. Cytotoxic etherphospholipid analogues. D Berkovic, Gen Pharmacol 1998 31 511 517 10.1016/S0306-3623(98)00081-0 9792208 (Pubitemid 28458917)
26. The effect of two synthetic phospholipids on cell proliferation and phosphatidylcholine biosynthesis in Madin-Darby canine kidney cells. T Wieder A Haase CC Geilen CE Orfanos, Lipids 1995 30 389 393 10.1007/BF02536296 7637558
27. Antagonism of phorbol-ester-stimulated phosphatidylcholine biosynthesis by the phospholipid analogue hexadecylphosphocholine. T Wieder CC Geilen W Reutter, Biochem J 1993 291 561 567 8387273
28. Hexadecylphosphocholine inhibits phosphatidylcholine biosynthesis and the proliferation of HepG2 cells. JM Jiménez-Lápez MP Carrasco JL Segovia C Marco, Eur J Biochem 2002 269 4649 4655 10.1046/j.1432-1033.2002. 03169.x 12230578
29. Hexadecylphosphocholine inhibits translocation of CTP:choline-phosphate cytidylyltransferase in Madin-Darby canine kidney cells. CC Geilen T Wieder W Reutter, J Biol Chem 1992 267 6719 6724 1313020
30. Alkylphosphocholines inhibit choline uptake and phosphatidylcholine biosynthesis in rat symphatetic neurons and impair axonal extension. E Posse de Chaves DE Vance RB Campenot JE Vance, Biochem J 1995 312 411 417 8526849
31. Effects of hexadecylphosphocholine on membrane phospholipid metabolism in human tumour cells. D Berkovic U Grunwald W Menzel C Unger W Hiddemann EA Fleer, Eur J Cancer 1995 31A 2080 2085 10.1016/0959-8049(95)00350-9 8562169
32. Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis. AH van der Luit M Budde P Ruurs M Verheij WJ van Blitterswijk, J Biol Chem 2002 277 39541 39547 10.1074/jbc.M203176200 12183451
33. A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. AH van der Luit SR Vink JB Klarenbeek D Perrissoud E Solary M Verheij WJ van Blitterswijk, Mol Cancer Ther 2007 6 2337 2345 10.1158/1535-7163.MCT-07-0202 17699729
34. The phospholipid analogue hexadecylphosphocholine inhibits phosphatidylcholine biosynthesis in Madin-Darby canine kidney cells. R Haase T Wieder CC Geilen W Reutter, FEBS Lett 1991 288 129 132 10.1016/0014-5793(91) 81018-4 1879545
35. Hexadecylphosphocholine disrupts cholesterol homeostasis and induces the accumulation of free cholesterol in HepG2 tumour cells. JM Jiménez- Lápez MP Carrasco C Marco JL Segovia, Biochem Pharmacol 2006 71 1114 1121 10.1016/j.bcp.2005.08.001 16466701
36. Hexadecylphosphocholine inhibits phosphatidylcholine synthesis via both the methylation of phosphatidylethanolamine and CDP-choline pathways in HepG2 cells. JM Jiménez-Lápez MP Carrasco JL Segovia C Marco, Int J Biochem Cell Biol 2004 36 153 161 10.1016/S1357-2725(03)00193-6 14592540
37. Effect of 1-O-octadecyl-2-O-methyl-glycerophosphocholine on phosphatidylcholine and phosphatidylethanolamine synthesis in MCF-7 and A549 cells and its relationship to inhibition of cell proliferation. X Zhou G Arthur, Eur J Biochem 1995 232 881 888 10.1111/j.1432-1033.1995.tb20887.x 7588730
38. Effects of hexadecylphosphocholine on phosphatidylcholine and phosphatidylserine metabolism in human lymphoma cells. D Berkovic S Sievers D Haase EA Fleer C Binder, J Exp Ther Oncol 2002 2 85 92 10.1046/j.1359-4117.2002. 01014.x 12415624
39. Hexadecylphosphocholine alters nonvesicular cholesterol traffic from the plasma membrane to the endoplasmic reticulum and inhibits the synthesis of sphingomyelin in HepG2 cells. C Marco JM Jiménez-Lápez P Ríos-Marco JL Segovia MP Carrasco, Int J Biochem Cell Biol 2009 41 1296 1303 10.1016/j.biocel.2008.11.004 19084611
40. Hexadecylphosphocholine does not influence phospholipase D and sphingomyelinase activity in human leukemia cells. D Berkovic K Berkovic C Binder D Haase EA Fleer, J Exp Ther Oncol 2002 2 213 218 10.1046/j.1359-4117. 2002.01036.x 12416025
41. Intracellular cholesterol transport. RE Soccio JL Breslow, Arterioscler Thromb Vasc Biol 2004 24 1150 1160 10.1161/01.ATV.0000131264.66417.d5 15130918
42. Cholesterol sensing, trafficking, and esterification. T Chang CCY Chang N Ohgami Y Yamauchi, Annu Rev Cell Dev Biol 2006 22 129 157 10.1146/annurev. cellbio.22.010305.104656 16753029
43. Dynamin is involved in endolysosomal cholesterol delivery to the endoplasmic reticulum: role in cholesterol homeostasis. P Robinet A Fradagrada M Monier M Marchetti A Cogny N Moatti J Paul B Vedie C Lamaze, Traffic 2006 7 811 823 10.1111/j.1600-0854.2006.00435.x 16787396
44. Distinct endosomal compartments in early trafficking of low density lipoprotein-derived cholesterol. S Sugii PC Reid N Ohgami H Du T Chang, J Biol Chem 2003 278 27180 27189 10.1074/jbc.M300542200 12721287
45. The fate of cholesterol exiting lysosomes. Y Lange J Ye J Chin, J Biol Chem 1997 272 17018 17022 10.1074/jbc.272.27.17018 9202016
46. Intracellular cholesterol transport. L Liscum NJ Munn, Biochim Biophys Acta 1999 1438 19 37 10216277
47. Cholesterol trafficking in the secretory and endocytic systems. W Prinz, Semin Cell Dev Biol 2002 13 197 203 10.1016/S1084-9521(02)00048-4 12137740
48. Protein sensors for membrane sterols. JL Goldstein RA DeBose-Boyd MS Brown, Cell 2006 124 35 46 10.1016/j.cell.2005.12.022 16413480
49. Intracellular sterol transport in eukaryotes, a connection to mitochondrial function? R Schneiter, Biochimie 2007 89 255 259 10.1016/j.biochi.2006.07.022 16945463
50. Development of an assay for the intermembrane transfer of cholesterol by Niemann-Pick C2 protein. JO Babalola M Wendeler B Breiden C Arenz G Schwarzmann S Locatelli-Hoops K Sandhoff, Biol Chem 2007 388 617 626 10.1515/BC.2007.063 17552909
51. Transport of cholesterol from the endoplasmic reticulum to the plasma membrane is constitutive in CaCo-2 cells and differs from the transport of plasma membrane cholesterol to the endoplasmic reticulum. FJ Field E Born S Murthy SN Mathur, J Lipid Res 1998 39 333 343 9507994
52. Circulation of cholesterol between lysosomes and the plasma membrane. Y Lange J Ye TL Steck, J Biol Chem 1998 273 18915 18922 10.1074/jbc.273.30.18915 9668068
53. Golgi localization and phosphorylation of oxysterol binding protein in Niemann-Pick C and U18666A-treated cells. A Mohammadi RJ Perry MK Storey HW Cook DM Byers ND Ridgway, J Lipid Res 2001 42 1062 1071 11441133
54. Cholesterol movement from plasma membrane to rough endoplasmic reticulum. Inhibition by progesterone. Y Lange, J Biol Chem 1994 269 3411 3414 8106380
55. Intracellular cholesterol trafficking: role of the NPC1 protein. EJ Blanchette-Mackie, Biochim Biophys Acta 2000 1486 171 183 10856720
56. Dynamics of lysosomal cholesterol in Niemann-Pick type C and normal human fibroblasts. Y Lange J Ye M Rigney TL Steck, J Lipid Res 2002 43 198 204 11861661
57. The transport of low density lipoprotein-derived cholesterol to the plasma membrane is defective in NPC1 cells. KM Wojtanik L Liscum, J Biol Chem 2003 278 14850 14856 10.1074/jbc.M300488200 12591922
58. Hexadecylphosphocholine interferes with the intracellular transport of cholesterol in HepG2 cells. MP Carrasco JM Jiménez-Lápez JL Segovia C Marco, FEBS J 2008 275 1675 1686 10.1111/j.1742-4658.2008.06322.x 18312412
59. Hexadecylphosphocholine interaction with lipid monolayers. M Rakotomanga PM Loiseau M Saint-Pierre-Chazalet, Biochim Biophys Acta 2004 1661 212 218 10.1016/j.bbamem.2004.01.010 15003884
60. Quantitation of the pool of cholesterol associated with acyl-CoA:cholesterol acyltransferase in human fibroblasts. Y Lange TL Steck, J Biol Chem 1997 272 13103 13108 10.1074/jbc.272.20.13103 9148923
61. Dissecting the role of the Golgi complex and lipid rafts in biosynthetic transport of cholesterol to the cell surface. S Heino S Lusa P Somerharju C Ehnholm VM Olkkonen E Ikonen, Proc Natl Acad Sci USA 2000 97 8375 8380 10.1073/pnas.140218797 10890900
62. Ezetimibe interferes with cholesterol trafficking from the plasma membrane to the ER in CaCo-2 cells. FJ Field K Watt SN Mathur, J Lipid Res 2007 48 1735 1745 10.1194/jlr.M700029-JLR200 17473178
63. Progesterone inhibits cholesterol biosynthesis in cultured cells. Accumulation of cholesterol precursors. JE Metherall K Waugh H Li, J Biol Chem 1996 271 2627 2633 10.1074/jbc.271.5.2627 8576232
64. Sphingomyelinase treatment induces ATP-independent endocytosis. X Zha LM Pierini PL Leopold PJ Skiba I Tabas FR Maxfield, J Cell Biol 1998 140 39 47 10.1083/jcb.140.1.39 9425152
65. Disruption of cellular cholesterol transport and homeostasis as a novel mechanism of action of membrane-targeted alkylphospholipid analogues. MP Carrasco JM Jiménez-Lápez P Ríos-Marco JL Segovia C Marco, Br J Pharmacol DOI:10.1111/j.1476-5381.2010.00689.x
66. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. JD Horton NA Shah JA Warrington NN Anderson SW Park MS Brown JL Goldstein, Proc Natl Acad Sci USA 2003 100 12027 12032 10.1073/pnas.1534923100 14512514
67. Regulation of intracellular cholesterol metabolism. R Sato T Takano, Cell Struct Funct 1995 20 421 427 10.1247/csf.20.421 8825062
68. Membrane rafts and signaling by the multichain immune recognition receptors. C Langlet AM Bernard P Drevot HT He, Curr Opin Immunol 2000 12 250 255 10.1016/S0952-7915(00)00084-4 10781401
69. Lipid rafts and signal transduction. K Simons D Toomre, Nat Rev Mol Cell Biol 2000 1 31 39 10.1038/35036052 11413487
70. Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy. SR Vink WJ van Blitterswijk JHM Schellens M Verheij, Cancer Treat Rev 2007 33 191 202 10.1016/j.ctrv.2006.12.001 17287087